The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions
RSV causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon.
Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study
Data on the protection conferred by COVID-19 vaccination and previous SARS-CoV-2 infection against omicron (B.1.1.529) infection in young children are scarce.
|
ESWI Airborne: Burden of Disease
Burden of disease - The economic and societal impact of acute respiratory viruses
The shocking numbers of babies and children who die, or who are in need of care, coupled with the rising number of undiagnosed older adults puts a significant burden from RSV on health systems.
Diagnosis of type 1 diabetes after SARS-CoV-2 infection: Researchers find possible correlation
Researchers at Helmholtz Munich and TU Dresden, in cooperation with the Kassenärztliche Vereinigung Bayern, have now investigated whether there is a temporal association between infection with the SARS-CoV-2 virus and the development of type 1 diabetes.
Reaching for New Heights: Breaking Down Influenza Trends and Prevention Efforts
Did you know that in female children, influenza pneumonia is the second most common cause of death?
Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study
Early-life severe RSV infection has been associated with the onset of childhood wheezing illnesses. However, the relationship between RSV infection during infancy and the development of childhood asthma is unclear.
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study
Accurate health-care burden data in healthy infants are necessary to determine RSV immunisation policy when RSV immunisation becomes available.
The Journey to RSV Vaccines — Heralding an Era of Structure-Based Design
After a 1960s RSV vaccine was found to enhance disease in previously unexposed infants, development was put on hold. But structure-based design has led to effective RSV vaccines that now await approval.
Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study
RSV infections cause an estimated 22-50 million episodes of acute lower respiratory infections (ALRI) every year in children younger than 5 years.
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine
This article assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510 [postfusion (post-F)] vaccine clinical trials.
Risk of Type 1 Diabetes in Children is Not Increased after SARS-CoV-2 Infection: A Nationwide Prospective Study in Denmark
It has been hypothesized that SARS-CoV-2 infection in children can increase risk of developing type 1 diabetes.
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
RSV infection in children is the most common viral respiratory infection and can cause severe lung damage or death. There is no licensed vaccine for preventing RSV infection.
